Gilead buys EpiTherapeutics to access Danish epigenetics expertise

Gilead Sciences has moved into epigenetic research by acquiring EpiTherapeutics for $65 million (€57 million) in cash. The deal gives it access to science originated at a team headed by Kristian Helin, a lauded oncology epigenetics expert and founder of Denmark’s Biotech Research and Innovation Centre.

Source: www.fiercebiotech.com

---